ClinicalTrials.gg
CompletedNCT00196976Updated Jun 8, 2018Results posted

Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old

A Phase 2 interventional study of Conjugated meningococcal ACWY-TT (vaccine) and DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib) in Infections, Meningococcal, sponsored by GlaxoSmithKline. Completed at 17 sites in 2 countries. Open to participants aged 12 Months to 60 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-08.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
461
Allocation
Randomized
Ages
12 Months to 60 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 71 studies in Meningococcal Infections by GlaxoSmithKline — none open to participants now, 1 under way, none of them phase 3. Meningococcal Infections · GlaxoSmithKline.

Enrollment
43rd of 67
461 · median 613
Started
2005
with 4 others
Phase 2
25 of 71
none open now
Registered
7th of 71
by date

Among the 71 studies in Meningococcal Infections by GlaxoSmithKline, this one is the 43rd largest by enrollment of the 67 interventional ones that give a count, is one of 5 that started in 2005, is one of 25 in phase 2, and was the 7th registered.

Meningococcal Infections

243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.

Browse Meningococcal Infections studies →

Open to participants now

None of the 71 studies in Meningococcal Infections by GlaxoSmithKline is open now. The open studies under Meningococcal Infections, anywhere →

Who these studies take

Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 12 Months to 60 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 71 studies in Meningococcal Infections by GlaxoSmithKline as a file.
02

Study summary

The purpose of this study is to evaluate the immunogenicity, safety and reactogenicity of one dose of four different formulations of the MenACWY conjugate vaccine when given to healthy children aged 12-14 months and 3-5 years. The selection of the best formulation will be based on data obtained up to one month after the vaccine dose.

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Read the detailed description

The study will enrol subjects of 12 to 14 months of age and subjects of 3 to 5 years of age. 3 formulations of GSK's MenACWY conjugate vaccine will be administered in a double-blind manner, while the 4th one will be single-blinded. Administration of the candidate vaccine or the active controls (MenC-CRM197 or Mencevax™ ACWY) will be done in an open manner. The study will be conducted in two stages: The primary vaccination phase (Study Stage 1) of the study will include all subjects; the second (booster/persistence) phase of the study (Study Stage 2) will include subjects in the active control groups and in the group which was primed with the selected MenACWY formulation.

The study will be conducted in a double-blind manner for groups receiving formulations A, B, C and in single blind manner with respect to the group receiving formulation D. The control vaccines will be administered in an open manner with respect to the investigational vaccination regimens.

Each group will have one blood sample prior to and one blood sample one month after the first vaccine dose.

03

Conditions studied

  • Infections, Meningococcal

Keywords

  • Safety
  • Meningococcal vaccine
  • Dose selection
  • Toddlers
  • Immunogenicity
  • Conjugate vaccine
  • Reactogenicity
  • Children
04

Who can participate

Ages eligible
12 Months to 60 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.
  • A male or female between, and including 12 and 14 months or 3 and 5 years of age at the time of the first vaccination.
  • Written obtained from the parent or guardian of the subject.
  • Free of obvious health problems as established by medical history and clinical examination before entering into the study.
  • Previously completed routine childhood vaccinations to the best of his/her parents'/guardians' knowledge. For pertussis vaccination, the children aged 12-14 months should have been vaccinated with an acellular pertussis vaccine.

Exclusion criteria

Exclusion criteria:

  • Use of any or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • Chronic administration (defined as more than 14 days) of or other immune-modifying drugs within six months prior to the first vaccine dose.
  • Planned administration/ administration of a vaccine not foreseen by the study protocol within one month of the first dose of vaccine and up to one month after administration of each study vaccine dose with the exception of oral polio vaccine (OPV).
  • Previous vaccination against meningococcal serogroup A, C, W-135 or Y disease.
  • Administration of a H. influenzae type b, diphtheria or tetanus vaccine within 3 months before the first dose of vaccine.
  • For subjects aged 12-14 months at enrolment:

    • For Austria: DTPa--IPV/Hib booster vaccination in the second year of life: these booster vaccines will be given at Visit 2.
    • For Greece: DTPa-IPV/Hib booster vaccination in the second year of life: these booster vaccines will be given at Visit 2.
  • History of meningococcal serogroup A, C, W-135 or Y disease.
  • Known exposure to meningococcal serogroup A, C, W-135 or Y disease within the previous year.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, including (HIV) infection.
  • A family history of congenital or hereditary immunodeficiency.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
  • Major congenital defects or serious chronic illness.
  • History of any neurologic disorders or seizures.
  • Acute disease at the time of enrolment.
  • Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Care provider)
Enrollment
461 participants (actual)

Study arms

  • Experimental
    GSK134612A Form1 (T), Primary Group

    Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.

    Biological: Conjugated meningococcal ACWY-TT (vaccine) · Biological: DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib) · Biological: DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™) · Biological: Mencevax™ACWY

  • Experimental
    GSK134612A Form2 (T), Primary Group

    Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.

    Biological: Conjugated meningococcal ACWY-TT (vaccine) · Biological: DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib) · Biological: DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)

  • Experimental
    GSK134612A Form3 (T), Primary Group

    Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.

    Biological: Conjugated meningococcal ACWY-TT (vaccine) · Biological: DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib) · Biological: DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)

  • Experimental
    GSK134612A Form4 (T), Primary Group

    Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.

    Biological: Conjugated meningococcal ACWY-TT (vaccine) · Biological: DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib) · Biological: DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)

  • Active comparator
    Control (T), Primary Group

    Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of Pfizer's Meningitec™ conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.

    Biological: DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib) · Biological: DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™) · Biological: Meningitec™ · Biological: Mencevax™ACWY

  • Experimental
    GSK134612A Form1 (C), Primary Group

    Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533).

    Biological: Conjugated meningococcal ACWY-TT (vaccine) · Biological: DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib) · Biological: DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)

  • Experimental
    GSK134612A Form2 (C), Primary Group

    Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533).

    Biological: Conjugated meningococcal ACWY-TT (vaccine) · Biological: DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib) · Biological: DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)

  • Experimental
    GSK134612A Form3 (C), Primary Group

    Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533).

    Biological: Conjugated meningococcal ACWY-TT (vaccine) · Biological: DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib) · Biological: DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)

  • Experimental
    GSK134612A Form4 (C), Primary Group

    Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533).

    Biological: Conjugated meningococcal ACWY-TT (vaccine) · Biological: DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib) · Biological: DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)

  • Active comparator
    Control (C), Primary Group

    Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of Mencevax™ ACWY vaccine, subcutaneously into the left upper arm, during this primary vaccination study (103533).

    Biological: Mencevax™ACWY

  • Experimental
    GSK134612A Form1 (T), Booster Group

    Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).

    Biological: Conjugated meningococcal ACWY-TT (vaccine) · Biological: Mencevax™ACWY

  • Active comparator
    Control (T), Booster Group

    Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with Pfizer's Meningitec™ conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).

    Biological: Meningitec™ · Biological: Mencevax™ACWY

  • Experimental
    GSK134612A Form1 (C), Booster Group

    Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, did not receive any booster vaccination.

    Biological: Conjugated meningococcal ACWY-TT (vaccine)

  • Active comparator
    Control (C), Booster Group

    Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, who 12 months after being primed with Pfizer's Meningitec™ conjugate vaccine, did not receive any booster vaccination.

    Biological: Meningitec™

Interventions

  • BiologicalConjugated meningococcal ACWY-TT (vaccine)

    One intramuscular dose during the primary vaccination

  • BiologicalDTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib)

    One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Greece only

  • BiologicalDTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)

    Drug page: Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccineStudies of Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccineDiphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Austria only

  • BiologicalMeningitec™

    One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age

  • BiologicalMencevax™ACWY

    One subcutaneous dose during the primary vaccination study in subjects of 3-5 years of age (Group E) and intramuscular administration of 1/5 dose during the booster vaccination study in subjects of 12-14 months of age (Groups A and E)

06

What researchers measure

Primary outcomes

  1. Number of Subjects With an Immune Response to Different Meningococcal Serogroups

    A responder to serum bactericidal assay meningococcal serogroups A, C, W and Y, using rabbit complement (rSBA-MenA, rSBA-MenC, rSBA-MenW-135, rSBA-MenY) was defined as follows: -for initially seronegative subjects (antibody titers \< 1:8 for rSBA-Men), a subject achieving a post-vaccination rSBA-Men antibody titer of ≥ 1:32; - for initially seropositive subjects (antibody titers ≥ 1:8 for rSBA-Men), a subject having a ≥ 4-fold increase in rSBA-Men antibody titer from pre to post vaccination.

    Time frame: One month after the first vaccine dose (Month 1)

Secondary outcomes

  1. Number of Seroprotected Subjects Against Different Meningococcal Serogroups

    A seroprotected subject against meningococcal serogroups rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY assessed, was defined as having antibody titers greater than or equal to (≥) 1:8.

    Time frame: Prior to (Month 0) and one month after (Month 1) the first vaccine dose

  2. Number of Seropositive Subjects for Different Anti-meningococcal Serogroups

    A seropositive subject for meningococcal serogroups rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-Y assessed, was defined as having antibody titers greater than or equal to (≥) 1:128.

    Time frame: Prior to (Month 0) and one month after (Month 1) after the first vaccine dose

  3. Antibody Titers Against Different Meningococcal Serogroups

    Antibody titers against meningococcal serogroups A, C, W-135 and Y (MenA, MenC, MenW-135 and MenY) have been assessed, using rabbit complement and expressed as geometric mean titers (GMTs).

    Time frame: Prior to (Month 0) and one month after (Month 1) the first vaccine dose

  4. Number of Seropositive Subjects for Different Anti-meningococcal Polysaccharides

    A seropositive subject for meningococcal polysaccharide A (PSA), C (PSC), W-135 (PSW-135) and Y (PSY) assessed, was defined as having antibody (anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY) concentrations greater than or equal to (≥) the cut-off value of 0.3 micrograms per milliliter (μg/mL). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA).

    Time frame: Prior to (Month 0) and one month after (Month 1) the first vaccine dose

  5. Number of Seroprotected Subjects Against Different Meningococcal Polysaccharides

    A seroprotected subject for meningococcal polysaccharide A (PSA), C (PSC), W-135 (PSW-135) and Y (PSY) assessed, was defined as having antibody (anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY) concentrations greater than or equal to (≥) the value of 2.0 micrograms per milliliter (μg/mL). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA).

    Time frame: Prior to (Month 0) and one month after (Month 1) the first vaccine dose

  6. Antibody Concentrations Against Different Meningococcal Polysaccharides

    The meningococcal polysaccharides assessed included polysaccharide A (anti-PSA), polysaccharide B (anti-PSB), polysaccharide W-135 (anti-PSW-135) and polysaccharide Y (anti-PSY). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL).

    Time frame: Prior to (Month 0) and one month after (Month 1) the first vaccine dose

  7. Number of Seropositive Subjects for Anti-tetanus (Anti-T)

    A seropositive subject for anti-tetanus was defined as having antibody concentrations greater than or equal to (≥) the cut-off value of 0.1 international units per milliliter (IU/mL). Antibody titers were determined by enzyme-linked immunosorbent assay (ELISA).

    Time frame: Prior to (Month 0) and one month after (Month 1) the first vaccine dose

  8. Antibody Concentrations Against Tetanus (Anti-T)

    Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA) method, presented as geometric mean concentrations (GMCs) and expressed in international units per milliliter (IU/mL).

    Time frame: Prior to (Month 0) and one month after (Month 1) the first vaccine dose

  9. Number of Toddlers With Any Solicited Local Symptoms

    The toddlers subgroup received 2 primary vaccine doses, as follows: first dose of a meningococcal vaccine and second dose of a diphtheria, tetanus and acellular pertusis-containing vaccine. Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.

    Time frame: During the 8-day (Days 0-7) post-vaccination period after each primary vaccine dose

  10. Number of Children With Any Solicited Local Symptoms

    The children subgroup received one dose of the meningococcal vaccine. Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.

    Time frame: During the 8-day (Days 0-7) post-vaccination period after each primary vaccine dose

  11. Number of Toddlers With Any Solicited General Symptoms

    The toddlers subgroup received 2 primary vaccine doses, as follows: first dose of a meningococcal vaccine and second dose of a diphtheria, tetanus and acellular pertusis-containing vaccine. Assessed solicited general symptoms included drowsiness, fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\], irritability and loss of appetite. Any = incidence of a particular symptom regardless of intensity or relationship to vaccination.

    Time frame: During the 8-day (Days 0-7) post-vaccination period after each primary vaccine dose

  12. Number of Children With Any Solicited General Symptoms

    The children subgroup received one primary meningococcal vaccine dose. Assessed solicited general symptoms included drowsiness, fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\], irritability and loss of appetite. Any = incidence of a particular symptom regardless of intensity or relationship to vaccination.

    Time frame: During the 8-day (Days 0-7) post-vaccination period after each primary vaccine dose

  13. Number of Seroprotected Subjects Against Different Meningococcal Serogroups

    A seroprotected subject against meningococcal serogroups rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY assessed, was defined as having antibody titers greater than or equal to (≥) 1:8.

    Time frame: At one month (M1) and 12 months (M12) post-primary vaccination

  14. Number of Seropositive Subjects for Different Anti-meningococcal Serogroups

    A seropositive subject for meningococcal serogroups rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-Y assessed, was defined as having antibody titers greater than or equal to (≥) 1:128.

    Time frame: At one month (M1) and 12 months (M12) post-primary vaccination

  15. Antibody Titers Against Different Meningococcal Serogroups

    Antibody titers against meningococcal serogroups A, C, W-135 and Y (MenA, MenC, MenW-135 and MenY) have been assessed, using rabbit complement and expressed as geometric mean titers (GMTs).

    Time frame: At one month (M1) and 12 months (M12) post-primary vaccination

  16. Number of Seropositive Subjects for Different Anti-meningococcal Polysaccharides

    A seropositive subject for meningococcal polysaccharide A (PSA), C (PSC), W-135 (PSW-135) and Y (PSY) assessed, was defined as having antibody (anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY) concentrations greater than or equal to (≥) the cut-off value of 0.3 micrograms per milliliter (μg/mL). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA).

    Time frame: At one month (M1) and 12 months (M12) post-primary vaccination

  17. Number of Seroprotected Subjects Against Different Meningococcal Polysaccharides

    A seroprotected subject for meningococcal polysaccharide A (PSA), C (PSC), W-135 (PSW-135) and Y (PSY) assessed, was defined as having antibody (anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY) concentrations greater than or equal to (≥) the value of 2.0 micrograms per milliliter (μg/mL). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA).

    Time frame: At one month (M1) and 12 months (M12) post primary vaccination

  18. Antibody Concentrations Against Different Meningococcal Polysaccharides

    The meningococcal polysaccharides assessed included polysaccharide A (anti-PSA), polysaccharide B (anti-PSB), polysaccharide W-135 (anti-PSW-135) and polysaccharide Y (anti-PSY). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL).

    Time frame: At one month (M1) and 12 months (M12) post-primary vaccination

  19. Number of Seropositive and Seroprotected Subjects Against Different Meningococcal Serogroups

    A seropositive subject for rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY was defined as a vaccinated subject with antibody titers greater than or equal to (≥) 1:128, while for a seroprotected subject, titers were ≥1:8.

    Time frame: Before (PRE= at Month 12) and one month after (at Month 13) booster vaccination

  20. Antibody Titers Against Different Meningococcal Serogroups

    Antibody titers against meningococcal serogroups A, C, W-135 and Y (MenA, MenC, MenW-135 and MenY) have been assessed, using rabbit complement and expressed as geometric mean titers (GMTs).

    Time frame: Before (PRE= at Month 12) and one month after (at Month 13) booster vaccination

  21. Number of Seropositive and Seroprotected Subjects Against Different Meningococcal Polysaccharides

    A seropositive subject for anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY was defined as a vaccinated subject with antibody concentrations greater than or equal to (≥) 0.3 micrograms per milliliter (μg/mL), while for a seroprotected subject, antibody concentrations were ≥ 2.0 μg/mL.

    Time frame: Before (PRE= at Month 12) and one month after (at Month 13) booster vaccination

  22. Antibody Concentrations Against Different Meningococcal Polysaccharides

    The meningococcal polysaccharides assessed included polysaccharide A (anti-PSA), polysaccharide B (anti-PSB), polysaccharide W-135 (anti-PSW-135) and polysaccharide Y (anti-PSY). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL).

    Time frame: Before (PRE= at Month 12) and one month after (at Month 13) booster vaccination

  23. Number of Subjects With Any Solicited Local Symptoms

    Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.

    Time frame: During the 8-day (Days 0-7) post-vaccination period following booster dose

  24. Number of Subjects With Any Solicited General Symptoms

    Assessed solicited general symptoms were drowsiness, fever \[defined as rectal temperature equal to or above 38.0 degrees Celsius (°C)\], irritability and loss of appetite. Any = incidence of a particular symptom regardless of intensity or relationship to vaccination.

    Time frame: During the 8-day (Days 0-7) post-vaccination period following booster dose

  25. Number of Subjects With Any Unsolicited Adverse Events (AEs) After the Primary Vaccination

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

    Time frame: Within 31 days (Days 0-30) after the primary meningococcal vaccination

  26. Number of Subjects With Any Unsolicited AEs During the Primary Vaccination

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

    Time frame: Within 31 days (Days 0-30) post-vaccination with diphteria, tetanus and acellular pertusis-containing vaccine, during the primary vaccination

  27. Number of Subjects With Any Unsolicited AEs

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

    Time frame: Within 31 days (Days 0-30) after the booster vaccination

  28. Number of Subjects With Serious Adverse Events (SAEs)

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: During the primary vaccination study (from Month 0 up to Month 2)

  29. Number of Subjects With SAEs

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: Since the last study contact in the primary study up to the end of the booster study (from Month 2 up to Month 13)

07

Results

Posted Mar 1, 2017
Limitations and caveats
None reported.

Participant flow

Primary Study
Participant flow — Primary Study
MilestoneGSK134612A Form1 (T), Primary GroupGSK134612A Form2 (T), Primary GroupGSK134612A Form3 (T), Primary GroupGSK134612A Form4 (T), Primary GroupControl (T), Primary GroupGSK134612A Form1 (C), Primary GroupGSK134612A Form2 (C), Primary GroupGSK134612A Form3 (C), Primary GroupGSK134612A Form4 (C), Primary GroupControl (C), Primary GroupGSK134612A Form1 (T), Booster GroupControl (T), Booster GroupGSK134612A Form1 (C), Booster GroupControl (C), Booster Group
Started394141404054505252520000
Completed384037393752504952510000
Not completed11413203010000
Withdrew: Migrated from study area00000001000000
Withdrew: Protocol violation01100000000000
Withdrew: Withdrawal by subject10112100010000
Withdrew: Lost to follow-up00001102000000
Withdrew: Other00200000000000
Booster Study
Participant flow — Booster Study
MilestoneGSK134612A Form1 (T), Primary GroupGSK134612A Form2 (T), Primary GroupGSK134612A Form3 (T), Primary GroupGSK134612A Form4 (T), Primary GroupControl (T), Primary GroupGSK134612A Form1 (C), Primary GroupGSK134612A Form2 (C), Primary GroupGSK134612A Form3 (C), Primary GroupGSK134612A Form4 (C), Primary GroupControl (C), Primary GroupGSK134612A Form1 (T), Booster GroupControl (T), Booster GroupGSK134612A Form1 (C), Booster GroupControl (C), Booster Group
Started000000000033324543
Completed000000000031304543
Not completed00000000002200
Withdrew: Withdrawal by subject00000000001000
Withdrew: Lost to follow-up00000000001200

Outcome measures

PrimaryNumber of Subjects With an Immune Response to Different Meningococcal Serogroups

A responder to serum bactericidal assay meningococcal serogroups A, C, W and Y, using rabbit complement (rSBA-MenA, rSBA-MenC, rSBA-MenW-135, rSBA-MenY) was defined as follows: -for initially seronegative subjects (antibody titers \< 1:8 for rSBA-Men), a subject achieving a post-vaccination rSBA-Men antibody titer of ≥ 1:32; - for initially seropositive subjects (antibody titers ≥ 1:8 for rSBA-Men), a subject having a ≥ 4-fold increase in rSBA-Men antibody titer from pre to post vaccination.

Time frame:
One month after the first vaccine dose (Month 1)
Reported as:
Count of participants · Participants
Number of Subjects With an Immune Response to Different Meningococcal Serogroups
ParticipantsGSK134612A Form1 (T), Primary GroupGSK134612A Form2 (T), Primary GroupGSK134612A Form3 (T), Primary GroupGSK134612A Form4 (T), Primary GroupControl (T), Primary GroupGSK134612A Form1 (C), Primary GroupGSK134612A Form2 (C), Primary GroupGSK134612A Form3 (C), Primary GroupGSK134612A Form4 (C), Primary GroupControl (C), Primary Group
rSBA-MenA3032262764138414236
rSBA-MenC30322633304544444634
rSBA-MenW-1353436273534644464836
rSBA-MenY3334263434647454734
SecondaryNumber of Seroprotected Subjects Against Different Meningococcal Serogroups

A seroprotected subject against meningococcal serogroups rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY assessed, was defined as having antibody titers greater than or equal to (≥) 1:8.

Time frame:
Prior to (Month 0) and one month after (Month 1) the first vaccine dose
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Different Meningococcal Serogroups
ParticipantsGSK134612A Form1 (T), Primary GroupGSK134612A Form2 (T), Primary GroupGSK134612A Form3 (T), Primary GroupGSK134612A Form4 (T), Primary GroupControl (T), Primary GroupGSK134612A Form1 (C), Primary GroupGSK134612A Form2 (C), Primary GroupGSK134612A Form3 (C), Primary GroupGSK134612A Form4 (C), Primary GroupControl (C), Primary Group
rSBA-MenA, Month 023221921204142404739
rSBA-MenA, Month 136383034235047485043
rSBA-MenC, Month 052253168171214
rSBA-MenC, Month 136382835345047474943
rSBA-MenW-135, Month 017191213153424253627
rSBA-MenW-135, Month 135383035155048485044
rSBA-MenY, Month 023171619223742394236
rSBA-MenY, Month 135382935255148485044
SecondaryNumber of Seropositive Subjects for Different Anti-meningococcal Serogroups

A seropositive subject for meningococcal serogroups rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-Y assessed, was defined as having antibody titers greater than or equal to (≥) 1:128.

Time frame:
Prior to (Month 0) and one month after (Month 1) after the first vaccine dose
Reported as:
Count of participants · Participants
Number of Seropositive Subjects for Different Anti-meningococcal Serogroups
ParticipantsGSK134612A Form1 (T), Primary GroupGSK134612A Form2 (T), Primary GroupGSK134612A Form3 (T), Primary GroupGSK134612A Form4 (T), Primary GroupControl (T), Primary GroupGSK134612A Form1 (C), Primary GroupGSK134612A Form2 (C), Primary GroupGSK134612A Form3 (C), Primary GroupGSK134612A Form4 (C), Primary GroupControl (C), Primary Group
rSBA-MenA, Month 019191319174139404637
rSBA-MenA, Month 136382934204947485043
rSBA-MenC, Month 03003194575
rSBA-MenC, Month 135342631274946454839
rSBA-MenW-135, Month 089448191191512
rSBA-MenW-135, Month 13538293595048484942
rSBA-MenY, Month 01711912172937323330
rSBA-MenY, Month 135372934185148485043
SecondaryAntibody Titers Against Different Meningococcal Serogroups

Antibody titers against meningococcal serogroups A, C, W-135 and Y (MenA, MenC, MenW-135 and MenY) have been assessed, using rabbit complement and expressed as geometric mean titers (GMTs).

Time frame:
Prior to (Month 0) and one month after (Month 1) the first vaccine dose
Reported as:
Geometric mean · Titers
Antibody Titers Against Different Meningococcal Serogroups
TitersGSK134612A Form1 (T), Primary GroupGSK134612A Form2 (T), Primary GroupGSK134612A Form3 (T), Primary GroupGSK134612A Form4 (T), Primary GroupControl (T), Primary GroupGSK134612A Form1 (C), Primary GroupGSK134612A Form2 (C), Primary GroupGSK134612A Form3 (C), Primary GroupGSK134612A Form4 (C), Primary GroupControl (C), Primary Group
rSBA-MenA, Month 084.2 (39.3 to 180.1)77.3 (32.9 to 181.6)68.4 (30.1 to 155.3)76 (33.8 to 170.8)69.1 (28.1 to 169.9)359.7 (212 to 610.4)367.2 (222.1 to 607)375.9 (227.4 to 621.2)465.2 (307.2 to 704.4)427.4 (280.3 to 651.7)
rSBA-MenA, Month 16648 (4787.3 to 9231.9)5406.8 (3961.5 to 7379.4)6225.2 (3510.2 to 11040.2)3928.6 (2851.5 to 5412.4)125.9 (53.1 to 298.3)7469.5 (5468.8 to 10202.1)7569.7 (6044 to 9480.6)13668.3 (11274.3 to 16570.6)4878 (4002.5 to 5944.9)4556.8 (3598 to 5771.1)
rSBA-MenC, Month 06.9 (4.1 to 11.5)4.5 (3.8 to 5.2)4.6 (3.8 to 5.7)6.6 (4.2 to 10.2)5.3 (3.8 to 7.3)12.5 (7.6 to 20.5)7.4 (4.7 to 11.6)11.8 (7.5 to 18.5)8.9 (5.7 to 14.1)11.9 (7 to 20.2)
rSBA-MenC, Month 1656.4 (483 to 892)495.7 (334.6 to 734.4)477.2 (245.1 to 929.4)464.3 (324.4 to 664.5)404.5 (222.5 to 735.4)967.6 (672 to 1393.3)1115 (746.4 to 1665.7)1738.8 (1159.7 to 2607)1197.6 (765 to 1874.7)378.3 (257.2 to 556.5)
rSBA-MenW-135, Month 019.8 (10.7 to 36.9)21.1 (11.5 to 38.6)14.5 (7.7 to 27.3)12.1 (7.1 to 20.6)18 (9.7 to 33.6)45.8 (27.9 to 75.2)22.3 (12.7 to 39)23.7 (14.2 to 39.7)44.6 (28.1 to 71)31.5 (18 to 55)
rSBA-MenW-135, Month 12781.4 (1647 to 4697.2)3447.5 (2484.8 to 4783.3)2545 (1522.2 to 4254.9)3260.8 (2342.1 to 4539.8)21.7 (10.5 to 44.9)4317.4 (3114.8 to 5984.3)3856.5 (3153.4 to 4716.4)5262.1 (4417.8 to 6267.7)4556.1 (3576.6 to 5803.7)912.7 (659.1 to 1264.1)
rSBA-MenY, Month 057.7 (27.5 to 121.3)24.4 (12 to 49.7)32.4 (14.3 to 73)32.9 (15.9 to 68.3)52.8 (25.5 to 109.5)98.7 (54.9 to 177.5)181.9 (112.1 to 295.3)146.8 (86.2 to 250.1)140.6 (82.8 to 238.9)123.6 (73.3 to 208.6)
rSBA-MenY, Month 12599.9 (1531.8 to 4412.7)2150.9 (1486.2 to 3112.9)1920.9 (1014.2 to 3638.2)3544.7 (2480.2 to 5065.9)75.6 (38.1 to 150.1)5249.1 (4107.9 to 6707.4)5150.5 (4149.8 to 6392.6)5896.3 (4686.4 to 7418.5)7548.4 (6116.1 to 9316.2)1527.3 (1110.8 to 2099.9)
SecondaryNumber of Seropositive Subjects for Different Anti-meningococcal Polysaccharides

A seropositive subject for meningococcal polysaccharide A (PSA), C (PSC), W-135 (PSW-135) and Y (PSY) assessed, was defined as having antibody (anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY) concentrations greater than or equal to (≥) the cut-off value of 0.3 micrograms per milliliter (μg/mL). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA).

Time frame:
Prior to (Month 0) and one month after (Month 1) the first vaccine dose
Reported as:
Count of participants · Participants
Number of Seropositive Subjects for Different Anti-meningococcal Polysaccharides
ParticipantsGSK134612A Form1 (T), Primary GroupGSK134612A Form2 (T), Primary GroupGSK134612A Form3 (T), Primary GroupGSK134612A Form4 (T), Primary GroupControl (T), Primary GroupGSK134612A Form1 (C), Primary GroupGSK134612A Form2 (C), Primary GroupGSK134612A Form3 (C), Primary GroupGSK134612A Form4 (C), Primary GroupControl (C), Primary Group
Anti-PSA, Month 0120101046910
Anti-PSA, Month 13536303424845484844
Anti-PSC, Month 01101134112
Anti-PSC, Month 133383035344945484844
Anti-PSW-135, Month 01011014201
Anti-PSW-135, Month 13436303504845484844
Anti-PSY, Month 02021124211
Anti-PSY, Month 13437303424945464844
SecondaryNumber of Seroprotected Subjects Against Different Meningococcal Polysaccharides

A seroprotected subject for meningococcal polysaccharide A (PSA), C (PSC), W-135 (PSW-135) and Y (PSY) assessed, was defined as having antibody (anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY) concentrations greater than or equal to (≥) the value of 2.0 micrograms per milliliter (μg/mL). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA).

Time frame:
Prior to (Month 0) and one month after (Month 1) the first vaccine dose
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Different Meningococcal Polysaccharides
ParticipantsGSK134612A Form1 (T), Primary GroupGSK134612A Form2 (T), Primary GroupGSK134612A Form3 (T), Primary GroupGSK134612A Form4 (T), Primary GroupControl (T), Primary GroupGSK134612A Form1 (C), Primary GroupGSK134612A Form2 (C), Primary GroupGSK134612A Form3 (C), Primary GroupGSK134612A Form4 (C), Primary GroupControl (C), Primary Group
Anti-PSA, Month 00000011025
Anti-PSA, Month 13535302504844473440
Anti-PSC, Month 00000022002
Anti-PSC, Month 133372934334445454744
Anti-PSW-135, Month 00000001000
Anti-PSW-135, Month 13327233204131413939
Anti-PSY, Month 00001012000
Anti-PSY, Month 13434273304640394742
SecondaryAntibody Concentrations Against Different Meningococcal Polysaccharides

The meningococcal polysaccharides assessed included polysaccharide A (anti-PSA), polysaccharide B (anti-PSB), polysaccharide W-135 (anti-PSW-135) and polysaccharide Y (anti-PSY). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL).

Time frame:
Prior to (Month 0) and one month after (Month 1) the first vaccine dose
Reported as:
Geometric mean · μg/mL
Antibody Concentrations Against Different Meningococcal Polysaccharides
μg/mLGSK134612A Form1 (T), Primary GroupGSK134612A Form2 (T), Primary GroupGSK134612A Form3 (T), Primary GroupGSK134612A Form4 (T), Primary GroupControl (T), Primary GroupGSK134612A Form1 (C), Primary GroupGSK134612A Form2 (C), Primary GroupGSK134612A Form3 (C), Primary GroupGSK134612A Form4 (C), Primary GroupControl (C), Primary Group
Anti-PSA, Month 00.16 (0.14 to 0.18)0.16 (0.14 to 0.19)0.15 (0.15 to 0.15)0.16 (0.14 to 0.17)0.15 (0.15 to 0.15)0.2 (0.17 to 0.25)0.17 (0.15 to 0.2)0.17 (0.15 to 0.19)0.21 (0.17 to 0.26)0.25 (0.18 to 0.35)
Anti-PSA, Month 130.65 (19.83 to 47.38)22.09 (16.35 to 29.84)34.68 (21.7 to 55.42)4.03 (2.72 to 5.98)0.17 (0.14 to 0.2)20.01 (14.53 to 27.56)12.62 (8.74 to 18.22)24.69 (19.14 to 31.85)3.63 (2.62 to 5.04)13.79 (9.04 to 21.02)
Anti-PSC, Month 00.16 (0.14 to 0.17)0.16 (0.14 to 0.17)0.15 (0.15 to 0.15)0.15 (0.15 to 0.16)0.16 (0.14 to 0.17)0.18 (0.15 to 0.22)0.18 (0.15 to 0.23)0.16 (0.14 to 0.17)0.15 (0.15 to 0.16)0.18 (0.14 to 0.22)
Anti-PSC, Month 110.67 (7.47 to 15.23)11.23 (8.75 to 14.4)12.91 (8.83 to 18.88)10.74 (8.43 to 13.68)11.99 (9.26 to 15.53)6.33 (4.81 to 8.34)7.76 (5.76 to 10.44)7.71 (6.05 to 9.83)7.78 (5.83 to 10.38)14.44 (11.32 to 18.42)
Anti-PSW-135, Month 00.15 (0.15 to 0.16)0.15 (0.15 to 0.15)0.16 (0.14 to 0.17)0.15 (0.15 to 0.16)0.15 (0.15 to 0.15)0.15 (0.15 to 0.16)0.17 (0.15 to 0.2)0.16 (0.15 to 0.17)0.15 (0.15 to 0.15)0.16 (0.14 to 0.17)
Anti-PSW-135, Month 17.52 (4.97 to 11.36)3.12 (2.3 to 4.22)3.62 (2.31 to 5.68)7.09 (5.19 to 9.7)0.15 (0.15 to 0.15)4.76 (3.4 to 6.66)3.2 (2.33 to 4.39)3.85 (2.85 to 5.21)4.99 (3.7 to 6.73)7.93 (5.39 to 11.66)
Anti-PSY, Month 00.16 (0.14 to 0.18)0.15 (0.15 to 0.15)0.16 (0.15 to 0.17)0.16 (0.14 to 0.2)0.15 (0.15 to 0.16)0.16 (0.14 to 0.18)0.19 (0.15 to 0.24)0.16 (0.15 to 0.17)0.15 (0.15 to 0.16)0.15 (0.15 to 0.16)
Anti-PSY, Month 110.86 (7.41 to 15.92)6.71 (5.12 to 8.8)6.01 (4 to 9.03)13.38 (9.48 to 18.89)0.16 (0.15 to 0.17)9.41 (6.66 to 13.31)6.59 (4.7 to 9.25)5.75 (4.23 to 7.81)11.7 (8.39 to 16.32)18.96 (13.68 to 26.29)
SecondaryNumber of Seropositive Subjects for Anti-tetanus (Anti-T)

A seropositive subject for anti-tetanus was defined as having antibody concentrations greater than or equal to (≥) the cut-off value of 0.1 international units per milliliter (IU/mL). Antibody titers were determined by enzyme-linked immunosorbent assay (ELISA).

Time frame:
Prior to (Month 0) and one month after (Month 1) the first vaccine dose
Reported as:
Count of participants · Participants
Number of Seropositive Subjects for Anti-tetanus (Anti-T)
ParticipantsGSK134612A Form1 (T), Primary GroupGSK134612A Form2 (T), Primary GroupGSK134612A Form3 (T), Primary GroupGSK134612A Form4 (T), Primary GroupControl (T), Primary GroupGSK134612A Form1 (C), Primary GroupGSK134612A Form2 (C), Primary GroupGSK134612A Form3 (C), Primary GroupGSK134612A Form4 (C), Primary GroupControl (C), Primary Group
Anti-T, Month 034363032334947464843
Anti-T, Month 136373035344847485043
SecondaryAntibody Concentrations Against Tetanus (Anti-T)

Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA) method, presented as geometric mean concentrations (GMCs) and expressed in international units per milliliter (IU/mL).

Time frame:
Prior to (Month 0) and one month after (Month 1) the first vaccine dose
Reported as:
Geometric mean · IU/mL
Antibody Concentrations Against Tetanus (Anti-T)
IU/mLGSK134612A Form1 (T), Primary GroupGSK134612A Form2 (T), Primary GroupGSK134612A Form3 (T), Primary GroupGSK134612A Form4 (T), Primary GroupControl (T), Primary GroupGSK134612A Form1 (C), Primary GroupGSK134612A Form2 (C), Primary GroupGSK134612A Form3 (C), Primary GroupGSK134612A Form4 (C), Primary GroupControl (C), Primary Group
Anti-T, Month 01.007 (0.671 to 1.51)1.159 (0.814 to 1.65)1.203 (0.871 to 1.662)1.293 (0.826 to 2.023)0.792 (0.578 to 1.084)1.426 (0.94 to 2.164)1.312 (0.935 to 1.841)1.232 (0.849 to 1.788)1.18 (0.823 to 1.694)1.083 (0.742 to 1.58)
Anti-T, Month 17.559 (5.04 to 11.335)5.353 (3.832 to 7.477)8.094 (4.855 to 13.492)7.675 (4.783 to 12.315)0.696 (0.52 to 0.932)17.284 (11.812 to 25.292)15.823 (11.728 to 21.348)19.369 (13.226 to 28.363)15.957 (11.767 to 21.639)1.231 (0.833 to 1.82)
SecondaryNumber of Toddlers With Any Solicited Local Symptoms

The toddlers subgroup received 2 primary vaccine doses, as follows: first dose of a meningococcal vaccine and second dose of a diphtheria, tetanus and acellular pertusis-containing vaccine. Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.

Time frame:
During the 8-day (Days 0-7) post-vaccination period after each primary vaccine dose
Reported as:
Count of participants · Participants
Number of Toddlers With Any Solicited Local Symptoms
ParticipantsGSK134612A Form1 (T), Primary GroupGSK134612A Form2 (T), Primary GroupGSK134612A Form3 (T), Primary GroupGSK134612A Form4 (T), Primary GroupControl (T), Primary Group
Pain, Dose 148364
Redness, Dose 191210911
Swelling, Dose 116764
Pain, Dose 2310676
Redness, Dose 2713987
Swelling, Dose 237973
SecondaryNumber of Children With Any Solicited Local Symptoms

The children subgroup received one dose of the meningococcal vaccine. Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.

Time frame:
During the 8-day (Days 0-7) post-vaccination period after each primary vaccine dose
Reported as:
Count of participants · Participants
Number of Children With Any Solicited Local Symptoms
ParticipantsGSK134612A Form1 (C), Primary GroupGSK134612A Form2 (C), Primary GroupGSK134612A Form3 (C), Primary GroupGSK134612A Form4 (C), Primary GroupControl (C), Primary Group
Pain101191113
Redness9111097
Swelling798104
SecondaryNumber of Toddlers With Any Solicited General Symptoms

The toddlers subgroup received 2 primary vaccine doses, as follows: first dose of a meningococcal vaccine and second dose of a diphtheria, tetanus and acellular pertusis-containing vaccine. Assessed solicited general symptoms included drowsiness, fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\], irritability and loss of appetite. Any = incidence of a particular symptom regardless of intensity or relationship to vaccination.

Time frame:
During the 8-day (Days 0-7) post-vaccination period after each primary vaccine dose
Reported as:
Count of participants · Participants
Number of Toddlers With Any Solicited General Symptoms
ParticipantsGSK134612A Form1 (T), Primary GroupGSK134612A Form2 (T), Primary GroupGSK134612A Form3 (T), Primary GroupGSK134612A Form4 (T), Primary GroupControl (T), Primary Group
Drowsiness, Dose 115445
Fever (Axillary), Dose 158835
Irritability, Dose 149655
Loss of appetite, Dose 116536
Drowsiness, Dose 222373
Fever (Axillary), Dose 245558
Irritability, Dose 267395
Loss of appetite, Dose 243262
SecondaryNumber of Children With Any Solicited General Symptoms

The children subgroup received one primary meningococcal vaccine dose. Assessed solicited general symptoms included drowsiness, fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\], irritability and loss of appetite. Any = incidence of a particular symptom regardless of intensity or relationship to vaccination.

Time frame:
During the 8-day (Days 0-7) post-vaccination period after each primary vaccine dose
Reported as:
Count of participants · Participants
Number of Children With Any Solicited General Symptoms
ParticipantsGSK134612A Form1 (C), Primary GroupGSK134612A Form2 (C), Primary GroupGSK134612A Form3 (C), Primary GroupGSK134612A Form4 (C), Primary GroupControl (C), Primary Group
Drowsiness42054
Fever (Axillary)44333
Irritability24247
Loss of appetite23263
SecondaryNumber of Seroprotected Subjects Against Different Meningococcal Serogroups

A seroprotected subject against meningococcal serogroups rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY assessed, was defined as having antibody titers greater than or equal to (≥) 1:8.

Time frame:
At one month (M1) and 12 months (M12) post-primary vaccination
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Different Meningococcal Serogroups
ParticipantsGSK134612A Form1 (T), Booster GroupControl (T), Booster GroupGSK134612A Form1 (C), Booster GroupControl (C), Booster Group
rSBA-MenA, Month 131184336
rSBA-MenC, Month 131294336
rSBA-MenW-135, Month 130114337
rSBA-MenY, Month 130204437
rSBA-MenA, Month 1223203933
rSBA-MenC, Month 1229254022
rSBA-MenW-135, Month 1230114131
rSBA-MenY, Month 1231234136
SecondaryNumber of Seropositive Subjects for Different Anti-meningococcal Serogroups

A seropositive subject for meningococcal serogroups rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-Y assessed, was defined as having antibody titers greater than or equal to (≥) 1:128.

Time frame:
At one month (M1) and 12 months (M12) post-primary vaccination
Reported as:
Count of participants · Participants
Number of Seropositive Subjects for Different Anti-meningococcal Serogroups
ParticipantsGSK134612A Form1 (T), Booster GroupControl (T), Booster GroupGSK134612A Form1 (C), Booster GroupControl (C), Booster Group
rSBA-MenA, Month 131144236
rSBA-MenC, Month 131234234
rSBA-MenW-135, Month 13064335
rSBA-MenY, Month 130134436
rSBA-MenA, Month 1223193932
rSBA-MenC, Month 1213152710
rSBA-MenW-135, Month 122764127
rSBA-MenY, Month 1230174032
SecondaryAntibody Titers Against Different Meningococcal Serogroups

Antibody titers against meningococcal serogroups A, C, W-135 and Y (MenA, MenC, MenW-135 and MenY) have been assessed, using rabbit complement and expressed as geometric mean titers (GMTs).

Time frame:
At one month (M1) and 12 months (M12) post-primary vaccination
Reported as:
Geometric mean · Titers
Antibody Titers Against Different Meningococcal Serogroups
TitersGSK134612A Form1 (T), Booster GroupControl (T), Booster GroupGSK134612A Form1 (C), Booster GroupControl (C), Booster Group
rSBA-MenA, Month 16577.8 (4606.7 to 9392.4)84.9 (32.4 to 222.8)6565.3 (4616.3 to 9337.2)4649.5 (3572.8 to 6050.8)
rSBA-MenC, Month 1660.4 (484.4 to 900.3)440.2 (227.1 to 853.1)893.6 (600.3 to 1330.3)416.2 (270.5 to 640.5)
rSBA-MenW-135, Month 12523.5 (1433.1 to 4443.7)17.2 (7.9 to 37.8)3893.6 (2671.2 to 5675.6)1004.4 (690.4 to 1461.2)
rSBA-MenY, Month 12483.9 (1363.8 to 4524.1)57.7 (27.1 to 123.2)4808.5 (3653 to 6329.6)1641.1 (1131.2 to 2380.9)
rSBA-MenA, Month 122369.1 (1642 to 3418.2)179.3 (76.1 to 422.9)2356.7 (1786.7 to 3108.4)1134.3 (767.8 to 1675.5)
rSBA-MenC, Month 12110.2 (60.6 to 200.7)122 (59 to 252.2)172.5 (117.7 to 252.9)41.7 (22 to 79.2)
rSBA-MenW-135, Month 12541.8 (305.5 to 961)18.9 (8.4 to 42.9)1322.2 (978.3 to 1786.8)181.7 (104.6 to 315.8)
rSBA-MenY, Month 12740.3 (493.4 to 1110.9)110.6 (51.6 to 237.1)1400.8 (1008.8 to 1945.1)347.2 (228.2 to 528.5)
SecondaryNumber of Seropositive Subjects for Different Anti-meningococcal Polysaccharides

A seropositive subject for meningococcal polysaccharide A (PSA), C (PSC), W-135 (PSW-135) and Y (PSY) assessed, was defined as having antibody (anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY) concentrations greater than or equal to (≥) the cut-off value of 0.3 micrograms per milliliter (μg/mL). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA).

Time frame:
At one month (M1) and 12 months (M12) post-primary vaccination
Reported as:
Count of participants · Participants
Number of Seropositive Subjects for Different Anti-meningococcal Polysaccharides
ParticipantsGSK134612A Form1 (T), Booster GroupControl (T), Booster GroupGSK134612A Form1 (C), Booster GroupControl (C), Booster Group
Anti-PSA, Month 13014137
Anti-PSC, Month 128304237
Anti-PSW-135, Month 12904137
Anti-PSY, Month 12924237
Anti-PSA, Month 122223434
Anti-PSC, Month 1213181836
Anti-PSW-135, Month 122533432
Anti-PSY, Month 122633435
SecondaryNumber of Seroprotected Subjects Against Different Meningococcal Polysaccharides

A seroprotected subject for meningococcal polysaccharide A (PSA), C (PSC), W-135 (PSW-135) and Y (PSY) assessed, was defined as having antibody (anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY) concentrations greater than or equal to (≥) the value of 2.0 micrograms per milliliter (μg/mL). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA).

Time frame:
At one month (M1) and 12 months (M12) post primary vaccination
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Different Meningococcal Polysaccharides
ParticipantsGSK134612A Form1 (T), Booster GroupControl (T), Booster GroupGSK134612A Form1 (C), Booster GroupControl (C), Booster Group
Anti-PSA, Month 13004133
Anti-PSC, Month 128293737
Anti-PSW-135, Month 12803432
Anti-PSY, Month 12903935
Anti-PSA, Month 121001222
Anti-PSC, Month 1224024
Anti-PSW-135, Month 12621023
Anti-PSY, Month 121511930
SecondaryAntibody Concentrations Against Different Meningococcal Polysaccharides

The meningococcal polysaccharides assessed included polysaccharide A (anti-PSA), polysaccharide B (anti-PSB), polysaccharide W-135 (anti-PSW-135) and polysaccharide Y (anti-PSY). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL).

Time frame:
At one month (M1) and 12 months (M12) post-primary vaccination
Reported as:
Geometric mean · µg/mL
Antibody Concentrations Against Different Meningococcal Polysaccharides
µg/mLGSK134612A Form1 (T), Booster GroupControl (T), Booster GroupGSK134612A Form1 (C), Booster GroupControl (C), Booster Group
Anti-PSA, Month 132.72 (20.12 to 53.22)0.17 (0.14 to 0.2)18.29 (12.86 to 26.01)13 (8.19 to 20.63)
Anti-PSC, Month 111.25 (7.48 to 16.93)12.43 (9.28 to 16.65)5.64 (4.21 to 7.57)14.5 (11.01 to 19.1)
Anti-PSW-135, Month 16.65 (4.29 to 10.3)0.15 (0.15 to 0.15)4.23 (2.94 to 6.09)8.17 (5.19 to 12.86)
Anti-PSY, Month 110.37 (6.74 to 15.94)0.16 (0.15 to 0.17)8.07 (5.79 to 11.24)18.12 (12.41 to 26.46)
Anti-PSA, Month 121.25 (0.68 to 2.3)0.17 (0.14 to 0.21)1.32 (0.9 to 1.95)4.43 (2.55 to 7.7)
Anti-PSC, Month 120.39 (0.23 to 0.66)0.54 (0.34 to 0.86)0.28 (0.22 to 0.36)2.9 (1.94 to 4.35)
Anti-PSW-135, Month 121.36 (1.06 to 1.74)0.21 (0.14 to 0.32)1.11 (0.79 to 1.57)3.16 (1.87 to 5.34)
Anti-PSY, Month 122.36 (1.75 to 3.18)0.21 (0.14 to 0.33)1.84 (1.2 to 2.82)6.9 (4.51 to 10.54)
SecondaryNumber of Seropositive and Seroprotected Subjects Against Different Meningococcal Serogroups

A seropositive subject for rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY was defined as a vaccinated subject with antibody titers greater than or equal to (≥) 1:128, while for a seroprotected subject, titers were ≥1:8.

Time frame:
Before (PRE= at Month 12) and one month after (at Month 13) booster vaccination
Reported as:
Count of participants · Participants
Number of Seropositive and Seroprotected Subjects Against Different Meningococcal Serogroups
ParticipantsGSK134612A Form1 (T), Booster GroupControl (T), Booster Group
rSBA-MenA ≥ 1:8, PRE2017
rSBA-MenC ≥ 1:8, PRE2520
rSBA-MenW-135 ≥ 1:8, PRE269
rSBA-MenY ≥ 1:8, PRE2718
rSBA-MenA ≥ 1:128, PRE2016
rSBA-MenC ≥ 1:128, PRE1012
rSBA-MenW-135 ≥ 1:128, PRE234
rSBA-MenY ≥ 1:128, PRE2614
rSBA-MenA ≥ 1:8, Month 13619
rSBA-MenC ≥ 1:8, Month 132524
rSBA-MenW-135 ≥ 1:8, Month 132521
rSBA-MenY ≥ 1:8, Month 132522
rSBA-MenA ≥ 1:128, Month 13619
rSBA-MenC ≥ 1:128, Month 132424
rSBA-MenW-135 ≥ 1:128, Month 132518
rSBA-MenY ≥ 1:128, Month 132520
SecondaryAntibody Titers Against Different Meningococcal Serogroups

Antibody titers against meningococcal serogroups A, C, W-135 and Y (MenA, MenC, MenW-135 and MenY) have been assessed, using rabbit complement and expressed as geometric mean titers (GMTs).

Time frame:
Before (PRE= at Month 12) and one month after (at Month 13) booster vaccination
Reported as:
Geometric mean · Titers
Antibody Titers Against Different Meningococcal Serogroups
TitersGSK134612A Form1 (T), Booster GroupControl (T), Booster Group
rSBA-MenA, PRE2163.4 (1436.6 to 3257.9)175.7 (70.5 to 437.8)
rSBA-MenC, PRE82.5 (50.3 to 135.4)102.5 (47.7 to 220.3)
rSBA-MenW-135, PRE436 (243.7 to 780.2)15.5 (7 to 34.3)
rSBA-MenY, PRE634.5 (420 to 958.3)93.6 (38.4 to 228.1)
rSBA-MenA, Month 133695.2 (1535.2 to 8894.7)984.6 (479.7 to 2021.2)
rSBA-MenC, Month 137067.4 (4070.7 to 12270.3)9209.3 (5153.4 to 16457.5)
rSBA-MenW-135, Month 135642.4 (3360 to 9475.4)255.6 (110.1 to 593.6)
rSBA-MenY, Month 133337.7 (2013.7 to 5532.1)323.8 (153.6 to 682.7)
SecondaryNumber of Seropositive and Seroprotected Subjects Against Different Meningococcal Polysaccharides

A seropositive subject for anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY was defined as a vaccinated subject with antibody concentrations greater than or equal to (≥) 0.3 micrograms per milliliter (μg/mL), while for a seroprotected subject, antibody concentrations were ≥ 2.0 μg/mL.

Time frame:
Before (PRE= at Month 12) and one month after (at Month 13) booster vaccination
Reported as:
Count of participants · Participants
Number of Seropositive and Seroprotected Subjects Against Different Meningococcal Polysaccharides
ParticipantsGSK134612A Form1 (T), Booster GroupControl (T), Booster Group
Anti-PSA ≥ 0.3 μg/mL, PRE191
Anti-PSC ≥ 0.3 μg/mL, PRE1115
Anti-PSW-135 ≥ 0.3 μg/mL, PRE232
Anti-PSY ≥ 0.3 μg/mL, PRE242
Anti-PSA ≥ 2.0 μg/mL, PRE70
Anti-PSC ≥ 2.0 μg/mL, PRE13
Anti-PSW-135 ≥ 2.0 μg/mL, PRE51
Anti-PSY ≥ 2.0 μg/mL, PRE140
Anti-PSA ≥ 0.3 μg/mL, Month 132619
Anti-PSC ≥ 0.3 μg/mL, Month 132522
Anti-PSW-135 ≥ 0.3 μg/mL, Month 132518
Anti-PSY ≥ 0.3 μg/mL, Month 132520
Anti-PSA ≥ 2.0 μg/mL, Month 132513
Anti-PSC ≥ 2.0 μg/mL, Month 132522
Anti-PSW-135 ≥ 2.0 μg/mL, Month 13249
Anti-PSY ≥ 2.0 μg/mL, Month 132412
SecondaryAntibody Concentrations Against Different Meningococcal Polysaccharides

The meningococcal polysaccharides assessed included polysaccharide A (anti-PSA), polysaccharide B (anti-PSB), polysaccharide W-135 (anti-PSW-135) and polysaccharide Y (anti-PSY). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL).

Time frame:
Before (PRE= at Month 12) and one month after (at Month 13) booster vaccination
Reported as:
Geometric mean · μg/mL
Antibody Concentrations Against Different Meningococcal Polysaccharides
μg/mLGSK134612A Form1 (T), Booster GroupControl (T), Booster Group
Anti-PSA, PRE0.98 (0.56 to 1.69)0.16 (0.14 to 0.18)
Anti-PSC, PRE1.33 (1.02 to 1.72)0.19 (0.13 to 0.27)
Anti-PSW-135, PRE25.67 (17.39 to 37.91)3.1 (1.34 to 7.2)
Anti-PSY, PRE56.94 (35.87 to 90.38)1.34 (0.63 to 2.88)
Anti-PSA, Month 130.32 (0.22 to 0.48)0.5 (0.31 to 0.8)
Anti-PSC, Month 132.34 (1.69 to 3.24)0.19 (0.13 to 0.26)
Anti-PSW-135, Month 1311.63 (7.73 to 17.5)15.23 (10.66 to 21.77)
Anti-PSY, Month 1379.03 (52.06 to 119.97)4.19 (2 to 8.78)
SecondaryNumber of Subjects With Any Solicited Local Symptoms

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.

Time frame:
During the 8-day (Days 0-7) post-vaccination period following booster dose
Reported as:
Count of participants · Participants
Number of Subjects With Any Solicited Local Symptoms
ParticipantsGSK134612A Form1 (T), Booster GroupControl (T), Booster Group
Any Pain10
Any Redness33
Any Swelling11
SecondaryNumber of Subjects With Any Solicited General Symptoms

Assessed solicited general symptoms were drowsiness, fever \[defined as rectal temperature equal to or above 38.0 degrees Celsius (°C)\], irritability and loss of appetite. Any = incidence of a particular symptom regardless of intensity or relationship to vaccination.

Time frame:
During the 8-day (Days 0-7) post-vaccination period following booster dose
Reported as:
Count of participants · Participants
Number of Subjects With Any Solicited General Symptoms
ParticipantsGSK134612A Form1 (T), Booster GroupControl (T), Booster Group
Any Drowsiness35
Any Fever (Rectally)53
Any Irritability45
Any Loss of appetite22
SecondaryNumber of Subjects With Any Unsolicited Adverse Events (AEs) After the Primary Vaccination

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

Time frame:
Within 31 days (Days 0-30) after the primary meningococcal vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Any Unsolicited Adverse Events (AEs) After the Primary Vaccination
ParticipantsGSK134612A Form1 (T), Primary GroupGSK134612A Form2 (T), Primary GroupGSK134612A Form3 (T), Primary GroupGSK134612A Form4 (T), Primary GroupControl (T), Primary GroupGSK134612A Form1 (C), Primary GroupGSK134612A Form2 (C), Primary GroupGSK134612A Form3 (C), Primary GroupGSK134612A Form4 (C), Primary GroupControl (C), Primary Group
Number of Subjects With Any Unsolicited Adverse Events (AEs) After the Primary Vaccination11165814612756
SecondaryNumber of Subjects With Any Unsolicited AEs During the Primary Vaccination

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

Time frame:
Within 31 days (Days 0-30) post-vaccination with diphteria, tetanus and acellular pertusis-containing vaccine, during the primary vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Any Unsolicited AEs During the Primary Vaccination
ParticipantsGSK134612A Form1 (T), Primary GroupGSK134612A Form2 (T), Primary GroupGSK134612A Form3 (T), Primary GroupGSK134612A Form4 (T), Primary GroupControl (T), Primary Group
Number of Subjects With Any Unsolicited AEs During the Primary Vaccination58557
SecondaryNumber of Subjects With Any Unsolicited AEs

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

Time frame:
Within 31 days (Days 0-30) after the booster vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Any Unsolicited AEs
ParticipantsGSK134612A Form1 (T), Booster GroupControl (T), Booster Group
Number of Subjects With Any Unsolicited AEs35
SecondaryNumber of Subjects With Serious Adverse Events (SAEs)

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Time frame:
During the primary vaccination study (from Month 0 up to Month 2)
Reported as:
Count of participants · Participants
Number of Subjects With Serious Adverse Events (SAEs)
ParticipantsGSK134612A Form1 (T), Primary GroupGSK134612A Form2 (T), Primary GroupGSK134612A Form3 (T), Primary GroupGSK134612A Form4 (T), Primary GroupControl (T), Primary GroupGSK134612A Form1 (C), Primary GroupGSK134612A Form2 (C), Primary GroupGSK134612A Form3 (C), Primary GroupGSK134612A Form4 (C), Primary GroupControl (C), Primary Group
Number of Subjects With Serious Adverse Events (SAEs)1111100000
SecondaryNumber of Subjects With SAEs

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Time frame:
Since the last study contact in the primary study up to the end of the booster study (from Month 2 up to Month 13)
Reported as:
Count of participants · Participants
Number of Subjects With SAEs
ParticipantsGSK134612A Form1 (T), Booster GroupControl (T), Booster GroupGSK134612A Form1 (C), Booster GroupControl (C), Booster Group
Number of Subjects With SAEs0000

Adverse events

Collected over Solicited symptoms: during the 8-day (Days 0-7) post-vaccination period. Unsolicited AEs: within 31 days (Days 0-30) after each vaccination. SAEs: from the beginning of the primary study up to the end of the booster study (from Month 0 up to Month 13).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GSK134612A Form1 (T), Primary Group0/39 (0%)1/39 (2.6%)20/39 (51.3%)
GSK134612A Form2 (T), Primary Group0/41 (0%)1/41 (2.4%)27/41 (65.9%)
GSK134612A Form3 (T), Primary Group0/41 (0%)1/41 (2.4%)23/41 (56.1%)
GSK134612A Form4 (T), Primary Group0/40 (0%)1/40 (2.5%)24/40 (60%)
Control (T), Primary Group0/40 (0%)1/40 (2.5%)25/40 (62.5%)
GSK134612A Form1 (C), Primary Group0/54 (0%)0/54 (0%)10/54 (18.5%)
GSK134612A Form2 (C), Primary Group0/50 (0%)0/50 (0%)11/50 (22%)
GSK134612A Form3 (C), Primary Group0/52 (0%)0/52 (0%)10/52 (19.2%)
GSK134612A Form4 (C), Primary Group0/52 (0%)0/52 (0%)11/52 (21.2%)
Control (C), Primary Group0/52 (0%)0/52 (0%)13/52 (25%)
GSK134612A Form1 (T), Booster Group0/33 (0%)0/33 (0%)5/33 (15.2%)
Control (T), Booster Group0/32 (0%)0/32 (0%)5/32 (15.6%)
GSK134612A Form1 (C), Booster Group0/45 (0%)0/45 (0%)—
Control (C), Booster Group0/43 (0%)0/43 (0%)—
Most frequent serious events
Most frequent serious events
EventGSK134612A Form1 (T), Primary GroupGSK134612A Form2 (T), Primary GroupGSK134612A Form3 (T), Primary GroupGSK134612A Form4 (T), Primary GroupControl (T), Primary GroupGSK134612A Form1 (C), Primary GroupGSK134612A Form2 (C), Primary GroupGSK134612A Form3 (C), Primary GroupGSK134612A Form4 (C), Primary GroupControl (C), Primary GroupGSK134612A Form1 (T), Booster GroupControl (T), Booster GroupGSK134612A Form1 (C), Booster GroupControl (C), Booster Group
Bronchiolitis (toddlers subgroup)Infections and infestations1/390/410/410/400/400/540/500/520/520/520/330/320/450/43
Maculo-papular rash (toddlers subgroup)Skin and subcutaneous tissue disorders0/390/410/410/401/400/540/500/520/520/520/330/320/450/43
Laryngitis (toddlers subgroup)Infections and infestations0/390/411/411/400/400/540/500/520/520/520/330/320/450/43
Acute bronchitis (toddlers subgroup)Infections and infestations0/391/410/410/400/400/540/500/520/520/520/330/320/450/43
Most frequent other events
Showing 10 of 22
Most frequent other events
EventGSK134612A Form1 (T), Primary GroupGSK134612A Form2 (T), Primary GroupGSK134612A Form3 (T), Primary GroupGSK134612A Form4 (T), Primary GroupControl (T), Primary GroupGSK134612A Form1 (C), Primary GroupGSK134612A Form2 (C), Primary GroupGSK134612A Form3 (C), Primary GroupGSK134612A Form4 (C), Primary GroupControl (C), Primary GroupGSK134612A Form1 (T), Booster GroupControl (T), Booster GroupGSK134612A Form1 (C), Booster GroupControl (C), Booster Group
Redness (Infanrix™-containing vaccine)General disorders7/3813/399/378/397/37—————————
Redness (GSK134612A conjugate vaccine)General disorders9/3812/4110/399/4011/399/5211/5010/509/527/513/313/30——
Pain (Infanrix™-containing vaccine)General disorders3/3810/396/377/396/37—————————
Pain (GSK134612A conjugate vaccine)General disorders4/388/413/396/404/3910/5211/509/5011/5213/511/310/30——
Swelling (Infanrix™-containing vaccine)General disorders3/387/399/377/393/37—————————
Irritability (Infanrix™-containing vaccine)General disorders6/387/393/379/395/37—————————
Irritability (GSK134612A conjugate vaccine)General disorders4/389/416/395/405/392/524/502/504/527/514/315/30——
Axillary fever (Infanrix™-containing vaccine)General disorders4/385/395/375/398/37—————————
Axillary/Rectally fever (GSK134612A conjugate vaccine)General disorders5/388/418/393/405/394/524/503/503/523/515/313/30——
Swelling (GSK134612A conjugate vaccine)General disorders1/386/417/396/404/397/529/508/5010/524/511/311/30——

Baseline characteristics

Age, Continuous
Age, Continuous(Months)GSK134612A Form1 (T), Primary GroupGSK134612A Form2 (T), Primary GroupGSK134612A Form3 (T), Primary GroupGSK134612A Form4 (T), Primary GroupControl (T), Primary GroupGSK134612A Form1 (C), Primary GroupGSK134612A Form2 (C), Primary GroupGSK134612A Form3 (C), Primary GroupGSK134612A Form4 (C), Primary GroupControl (C), Primary GroupGSK134612A Form1 (T), Booster GroupControl (T), Booster GroupGSK134612A Form1 (C), Booster GroupControl (C), Booster GroupTotal
Mean12.5 ± 0.8212.8 ± 0.8612.8 ± 0.8612.9 ± 0.8312.8 ± 0.7948.1 ± 7.1248 ± 7.2247.8 ± 7.0148 ± 7.7847.7 ± 7.15NA ± NANA ± NANA ± NANA ± NA32.59 ± 4.45
Age, Continuous
Age, Continuous(Months)GSK134612A Form1 (T), Primary GroupGSK134612A Form2 (T), Primary GroupGSK134612A Form3 (T), Primary GroupGSK134612A Form4 (T), Primary GroupControl (T), Primary GroupGSK134612A Form1 (C), Primary GroupGSK134612A Form2 (C), Primary GroupGSK134612A Form3 (C), Primary GroupGSK134612A Form4 (C), Primary GroupControl (C), Primary GroupGSK134612A Form1 (T), Booster GroupControl (T), Booster GroupGSK134612A Form1 (C), Booster GroupControl (C), Booster GroupTotal
MeanNA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA24.9 ± 1.2424.9 ± 1.2760.8 ± 7.2360.0 ± 7.3645.32 ± 18.47
Sex: Female, Male
Sex: Female, Male(Participants)GSK134612A Form1 (T), Primary GroupGSK134612A Form2 (T), Primary GroupGSK134612A Form3 (T), Primary GroupGSK134612A Form4 (T), Primary GroupControl (T), Primary GroupGSK134612A Form1 (C), Primary GroupGSK134612A Form2 (C), Primary GroupGSK134612A Form3 (C), Primary GroupGSK134612A Form4 (C), Primary GroupControl (C), Primary GroupGSK134612A Form1 (T), Booster GroupControl (T), Booster GroupGSK134612A Form1 (C), Booster GroupControl (C), Booster GroupTotal
Female15151724192116232727NANANANANA
Male24262416213334292525NANANANANA
Sex: Female, Male
Sex: Female, Male(Participants)GSK134612A Form1 (T), Primary GroupGSK134612A Form2 (T), Primary GroupGSK134612A Form3 (T), Primary GroupGSK134612A Form4 (T), Primary GroupControl (T), Primary GroupGSK134612A Form1 (C), Primary GroupGSK134612A Form2 (C), Primary GroupGSK134612A Form3 (C), Primary GroupGSK134612A Form4 (C), Primary GroupControl (C), Primary GroupGSK134612A Form1 (T), Booster GroupControl (T), Booster GroupGSK134612A Form1 (C), Booster GroupControl (C), Booster GroupTotal
FemaleNANANANANANANANANANA11151623NA
MaleNANANANANANANANANANA22172920NA
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GSK134612A Form1 (T), Primary GroupGSK134612A Form2 (T), Primary GroupGSK134612A Form3 (T), Primary GroupGSK134612A Form4 (T), Primary GroupControl (T), Primary GroupGSK134612A Form1 (C), Primary GroupGSK134612A Form2 (C), Primary GroupGSK134612A Form3 (C), Primary GroupGSK134612A Form4 (C), Primary GroupControl (C), Primary GroupGSK134612A Form1 (T), Booster GroupControl (T), Booster GroupGSK134612A Form1 (C), Booster GroupControl (C), Booster GroupTotal
White/ Caucasian38404038395350505051NANANANANA
Arabic/ north african1010110210NANANANANA
East/ south east asian0101000000NANANANANA
Black0001000011NANANANANA
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GSK134612A Form1 (T), Primary GroupGSK134612A Form2 (T), Primary GroupGSK134612A Form3 (T), Primary GroupGSK134612A Form4 (T), Primary GroupControl (T), Primary GroupGSK134612A Form1 (C), Primary GroupGSK134612A Form2 (C), Primary GroupGSK134612A Form3 (C), Primary GroupGSK134612A Form4 (C), Primary GroupControl (C), Primary GroupGSK134612A Form1 (T), Booster GroupControl (T), Booster GroupGSK134612A Form1 (C), Booster GroupControl (C), Booster GroupTotal
White/CaucasianNANANANANANANANANANA32314443NA
Arabic/north AfricanNANANANANANANANANANA1110NA
08

Study locations

17 sites
  • GSK Investigational Site
    Eferding, A-4070, Austria
  • GSK Investigational Site
    Graz, A-8036, Austria
  • GSK Investigational Site
    Salzburg, A-5020, Austria
  • GSK Investigational Site
    Vienna, A-1020, Austria
  • GSK Investigational Site
    Villach, A-9500, Austria
  • GSK Investigational Site
    Wels, A-4600, Austria
  • GSK Investigational Site
    Athens, 11527, Greece
  • GSK Investigational Site
    Heraklion, Crete, 71110, Greece
  • GSK Investigational Site
    Ioannina, 452 21, Greece
  • GSK Investigational Site
    Komotini, 69100, Greece
  • GSK Investigational Site
    Koufalia, 571 00, Greece
  • GSK Investigational Site
    Markopoulo, 19003, Greece
  • GSK Investigational Site
    N. Efkarpia, Thessaloniki, 564 29, Greece
  • GSK Investigational Site
    Nea Makri, 19005, Greece
  • GSK Investigational Site
    Rio/Patras, 26500, Greece
  • GSK Investigational Site
    Thessaloniki, 54636, Greece
  • GSK Investigational Site
    Tripolis, 22100, Greece
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2005, a primary completion of Mar 2006 and a completion of Mar 2006. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 11 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2005
First posted
Sep 20, 2005
Start
Mar 24, 2005
Primary completionActual
Mar 1, 2006
CompletionActual
Mar 3, 2006
Results first posted
Mar 1, 2017
Last update
Jun 8, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00196976
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 20, 2005
Start date
Mar 24, 2005
Primary completion
Mar 1, 2006
Completion
Mar 3, 2006
Results posted
Mar 1, 2017
Last update
Jun 8, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine

Start the discussion